Evidence map›Paper›PMID 31391192›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Hailing Yang, Zhang Shu, Yongying Jiang, Weiqun Mao, Lan Pang, Abena Redwood, Sabrina L Jeter-Jones, Nicholas B Jennings, Argentina Ornelas, Jinhua Zhou and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. The Warburg Effect and Aerobic Glycolysis in Tumors.Cancer treatment and research · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Antiviral Effect of Polyphenolic Substances inEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  14. Article
  15. Article
  16. Impact of Hypoxia over Human Viral Infections and Key Cellular Processes.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Article
  19. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.Journal of experimental & clinical cancer research : CR · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 3 countries.

Hailing YangDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Zhang ShuDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Yongying JiangInstitute for Applied Cancer Science, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Weiqun MaoDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Lan PangDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Abena RedwoodDepartment of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Sabrina L Jeter-JonesDepartment of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Nicholas B JenningsDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Argentina OrnelasCancer Systems Imaging, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Jinhua ZhouDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Geoffrey BartholomeuszDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
LaKesla R IlesDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Niki M ZachariasDepartment of Urology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Steven W MillwardCancer Systems Imaging, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Xiao-Feng LeDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Ahmed A AhmedOvarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom.
Helen Piwnica-WormsDepartment of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Robert C BastDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas. [email protected] [email protected].
Zhen LuDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas. [email protected] [email protected].
The University of Texas MD Anderson Cancer Center · USJohn Radcliffe Hospital · GB

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
Targeted Molecular Imaging of Cell Death in Ovarian CancerR21CA181994 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, ZHEN, MILLWARD, STEVEN W · 2016 to 2017
$383k
Medical Research Council G0902418NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA217685NCI NIH HHS R21 CA181994NCI NIH HHS R35 CA209904
6 · The paper itself

Abstract

purposePaclitaxel is an integral component of primary therapy for breast and epithelial ovarian cancers, but less than half of these cancers respond to the drug. Enhancing the response to primary therapy with paclitaxel could improve outcomes for women with both diseases.

resultsKnockdown of

conclusionsPFKFB2 is a novel target whose inhibition can enhance the effect of paclitaxel-based primary chemotherapy upon ovarian and breast cancers retaining wt

Indexed as

Drug Resistance, NeoplasmAnimalsBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationDisease Models, AnimalFemaleGene ExpressionGene SilencingHumansImmunohistochemistryMetabolic Networks and PathwaysMiceMutationOvarian NeoplasmsPaclitaxelPFKFB2 protein, humanPhosphofructokinase-2Reactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID31391192
PMCPMC6744996
OpenAlexW2964879100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.